ERBB2 and breast cancer: In a clinical trial, patients with Her2+ BC were randomized into two groups: one receiving pertuzumab, trastuzumab, and docetaxel (pertuzumab combination), and the other receiving trastuzumab and docetaxel (placebo combination).